MA38656A1 - Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose - Google Patents

Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Info

Publication number
MA38656A1
MA38656A1 MA38656A MA38656A MA38656A1 MA 38656 A1 MA38656 A1 MA 38656A1 MA 38656 A MA38656 A MA 38656A MA 38656 A MA38656 A MA 38656A MA 38656 A1 MA38656 A1 MA 38656A1
Authority
MA
Morocco
Prior art keywords
inhibitor
cancer
mps
kinase
treatment
Prior art date
Application number
MA38656A
Other languages
English (en)
Inventor
Gerhard Siemeister
Antje Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48576906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38656(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38656A1 publication Critical patent/MA38656A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose. La présente invention concerne en outre l'utilisation de ladite combinaison pour le traitement d'un cancer, en particulier du cancer du pancréas, d'un glioblastome, du cancer de l'ovaire, d'un carcinome pulmonaire non à petites cellules, du cancer du sein et/ou du cancer gastrique.
MA38656A 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose MA38656A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171517 2013-06-11
PCT/EP2014/061772 WO2014198645A1 (fr) 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Publications (1)

Publication Number Publication Date
MA38656A1 true MA38656A1 (fr) 2018-05-31

Family

ID=48576906

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38656A MA38656A1 (fr) 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Country Status (16)

Country Link
US (1) US20160128988A1 (fr)
EP (1) EP3007692A1 (fr)
JP (1) JP2016520665A (fr)
KR (1) KR20160018534A (fr)
CN (1) CN105283178A (fr)
AU (1) AU2014280354A1 (fr)
CA (1) CA2914742A1 (fr)
CL (1) CL2015003585A1 (fr)
EA (1) EA201600003A1 (fr)
HK (1) HK1219879A1 (fr)
MA (1) MA38656A1 (fr)
MX (1) MX2015017120A (fr)
PH (1) PH12015502757A1 (fr)
SG (1) SG11201509350RA (fr)
TN (1) TN2015000543A1 (fr)
WO (1) WO2014198645A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
KR20230020560A (ko) * 2016-04-15 2023-02-10 펠리시텍스 쎄라퓨틱스, 인코포레이티드 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합
RU2769527C2 (ru) 2016-06-22 2022-04-01 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
CN106117202B (zh) * 2016-06-29 2018-06-26 四川大学华西医院 具有抗肿瘤活性的[1,2,4]三唑并[1,5-a]吡啶衍生物晶型
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
WO2023165603A1 (fr) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Inhibiteur d'adn-pk et son utilisation en combinaison

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
EP1440973A3 (fr) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Dérivés d'épothilone, procédé de production et utilisation
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
EP0923583A1 (fr) 1996-08-30 1999-06-23 Novartis AG Procede de fabrication d'epothilones, et composes intermediaires obtenus au cours de ce procede
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19880193D2 (de) 1997-02-25 2000-08-24 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte Epothilone
US5902822A (en) 1997-02-28 1999-05-11 Bristol-Myers Squibb Company 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6384230B1 (en) 1997-07-16 2002-05-07 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
IL135590A (en) 1997-12-04 2003-09-17 Bristol Myers Squibb Co Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
EP2343295A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
EP2343294A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
PL2699575T3 (pl) * 2011-04-21 2015-08-31 Bayer Ip Gmbh Triazolopirydyny
WO2012160029A1 (fr) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Triazolopyridines substituées
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
NZ703020A (en) 2012-07-10 2017-08-25 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (fr) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer

Also Published As

Publication number Publication date
JP2016520665A (ja) 2016-07-14
EP3007692A1 (fr) 2016-04-20
KR20160018534A (ko) 2016-02-17
MX2015017120A (es) 2016-10-05
CN105283178A (zh) 2016-01-27
SG11201509350RA (en) 2015-12-30
EA201600003A1 (ru) 2016-06-30
TN2015000543A1 (en) 2017-04-06
PH12015502757A1 (en) 2016-03-21
CA2914742A1 (fr) 2014-12-18
HK1219879A1 (zh) 2017-04-21
AU2014280354A1 (en) 2015-12-03
CL2015003585A1 (es) 2016-07-08
WO2014198645A1 (fr) 2014-12-18
US20160128988A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
MA38656A1 (fr) Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
EA202091540A1 (ru) Антитела к lilrb2
MA41013B1 (fr) Compositions comprenant des souches bactériennes
EP3575795A3 (fr) Biomarqueurs salivaires pour cancer du sein
EP3934645A4 (fr) Utilisation du catequentinib (anlotinib) en combinaison avec une chimiothérapie standard ou une immunothérapie standard pour le traitement du cancer
MA39034A1 (fr) Composés de quinoline sélectivement substitués
HK1214652A1 (zh) 用於检测胰腺癌的方法和组合物
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
UA117470C2 (uk) Заміщені ксантини та способи їх застосування
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
MY173126A (en) Arylquinazolines
MA40061A (fr) Compositions immunogènes à base de listeria pour provoquer des réponses anti-tumorales
IN2014DN05885A (fr)
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
EP3356684A4 (fr) Combinaison de bloc collecteur, de boîtier de soupape et d'ensemble tiroir de commande pour bloc collecteur
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
BR112015018433A2 (pt) indicador de desgaste em um sistema composto feito de tijolos de cerâmica à prova de fogo
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX388832B (es) Deteccion especifica de isoformas de clusterina.
MX369175B (es) Métodos para detectar mutantes de akt resistentes a fármacos.
MA38654B1 (fr) Dérivés de type promédicament de triazolopyridines substituées